[August 29, 2016]

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Pipeline Review 2016 Featuring Cytheris, Genexine, GlaxoSmithKline, OSE Immunotherapeutics & Pfizer - Research and Markets

Research and Markets has announced the addition of the "Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016" report to their offering.

'Interleukin 7 Receptor Subunit Alpha - Pipeline Review, H1 2016'; Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) pipeline Target (News - Alert) constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities

Institutes.

Furthermore, the author says; Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin-7. It acts as a receptor for thymic stromal lymphopoietin (TSLP). It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis.

The report 'Interleukin 7 Receptor Subunit Alpha - Pipeline Review, H1 2016' outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Key Topics Covered:

1. Introduction
2. Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Overview
3. Therapeutics Development
4. Pipeline Products for Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Overview
5. Pipeline Products for Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Comparative Analysis
6. Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Therapeutics under Development by Companies
7. Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Therapeutics under Investigation by Universities/Institutes
8. Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Products under Development by Companies
13. Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Products under Investigation by Universities/Institutes
14. Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Companies Involved in Therapeutics Development

• Cytheris SA
• Genexine, Inc.
• GlaxoSmithKline Plc
• OSE Immunotherapeutics
• Pfizer Inc.

For more information about this report visit http://www.researchandmarkets.com/research/dn5v3k/interleukin_7

Related Topics: Immune Disorders Drugs

View source version on businesswire.com: http://www.businesswire.com/news/home/20160829005870/en/

[ Back To TMCnet.com's Homepage ]